Literature DB >> 19802003

c-Kit mutants require hypoxia-inducible factor 1alpha to transform melanocytes.

G Monsel1, N Ortonne, M Bagot, A Bensussan, N Dumaz.   

Abstract

Many studies have highlighted the critical role of c-Kit in normal melanocyte development but its role in melanoma development remains unclear. Although c-Kit expression is often lost during melanoma progression, a subset of melanoma has been found to overexpress c-Kit and mutations activating c-Kit have recently been identified in some acral and mucosal melanoma. To address the role of these c-Kit mutants in the transformation of melanocytes, we characterized the physiological responses of melanocytes expressing the most frequent c-Kit mutants found in melanoma (K642E and L576P) and a novel mutant we identified in an acral melanoma. We analysed signaling pathways activated downstream of c-Kit and showed that all three mutants led to a strong activation of the phosphatidyl-inositol-3 kinase (PI3K) pathway but only weak activation of the Ras/Raf/Mek/Erk pathway, which was not sufficient to promote uncontrolled melanocyte proliferation and transformation. However, in hypoxic conditions or coexpressed with a constitutively active form of hypoxia-inducible factor 1alpha (HIF-1alpha), c-Kit mutants activate the Ras/Raf/Mek/Erk pathway, stimulate proliferation and transform melanocytes. Proliferation of melanocytes transformed by these mutants was specifically inhibited by imatinib. These results show for the first time that melanocytes require a specific epigenetic environment to be transformed by c-Kit mutants and highlight a distinct molecular mechanism of melanocyte transformation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19802003     DOI: 10.1038/onc.2009.320

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  29 in total

Review 1.  Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics.

Authors:  Scott E Woodman; Michael A Davies
Journal:  Biochem Pharmacol       Date:  2010-05-08       Impact factor: 5.858

Review 2.  Delving into somatic variation in sporadic melanoma.

Authors:  Vijay Walia; Euphemia W Mu; Jimmy C Lin; Yardena Samuels
Journal:  Pigment Cell Melanoma Res       Date:  2012-02-13       Impact factor: 4.693

3.  A new KIT mutation (N505I) in acral melanoma confers constitutive signaling, favors tumorigenic properties, and is sensitive to imatinib.

Authors:  Maryline Allegra; Damien Giacchero; Coralie Segalen; Nicolas Dumaz; Catherine Butori; Véronique Hofman; Paul Hofman; Jean-Philippe Lacour; Corine Bertolotto; Philippe Bahadoran; Robert Ballotti
Journal:  J Invest Dermatol       Date:  2013-12-06       Impact factor: 8.551

4.  Guidelines for biomarker testing in metastatic melanoma: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.

Authors:  S Martín-Algarra; M T Fernández-Figueras; J A López-Martín; A Santos-Briz; A Arance; M D Lozano; A Berrocal; J J Ríos-Martín; E Espinosa; J L Rodríguez-Peralto
Journal:  Clin Transl Oncol       Date:  2013-10-16       Impact factor: 3.405

5.  Genotyping of cutaneous melanoma.

Authors:  Isabella C Glitza; Michael A Davies
Journal:  Chin Clin Oncol       Date:  2014-09

6.  Hypoxia and MITF regulate KIT oncogenic properties in melanocytes.

Authors:  F Laugier; J Delyon; J André; A Bensussan; N Dumaz
Journal:  Oncogene       Date:  2016-03-14       Impact factor: 9.867

7.  CK1α ablation in keratinocytes induces p53-dependent, sunburn-protective skin hyperpigmentation.

Authors:  Chung-Hsing Chang; Che-Jung Kuo; Takamichi Ito; Yu-Ya Su; Si-Tse Jiang; Min-Hsi Chiu; Yi-Hsiung Lin; Andrea Nist; Marco Mernberger; Thorsten Stiewe; Shosuke Ito; Kazumasa Wakamatsu; Yi-An Hsueh; Sheau-Yann Shieh; Irit Snir-Alkalay; Yinon Ben-Neriah
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-06       Impact factor: 11.205

8.  Identification of the hypoxia-inducible factor 2α nuclear interactome in melanoma cells reveals master proteins involved in melanoma development.

Authors:  Anne-Lise Steunou; Manuelle Ducoux-Petit; Ikrame Lazar; Bernard Monsarrat; Monique Erard; Catherine Muller; Eric Clottes; Odile Burlet-Schiltz; Laurence Nieto
Journal:  Mol Cell Proteomics       Date:  2012-12-28       Impact factor: 5.911

Review 9.  The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia.

Authors:  Boris C Bastian
Journal:  Annu Rev Pathol       Date:  2014       Impact factor: 23.472

10.  GAB2 induces tumor angiogenesis in NRAS-driven melanoma.

Authors:  Y Yang; J Wu; A Demir; M Castillo-Martin; R D Melamed; G Zhang; M Fukunaga-Kanabis; R Perez-Lorenzo; B Zheng; D N Silvers; G Brunner; S Wang; R Rabadan; C Cordon-Cardo; J T Celebi
Journal:  Oncogene       Date:  2012-08-27       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.